Prevnar 20 (PCV20) is a 20-valent pneumococcal conjugate vaccine (PCV) manufactured by Wyeth (Pfizer) pharmaceuticals, containing Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F,14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. Prevnar 20 does not protect against infection and disease caused by Streptococcus pneumoniae strains not present in the vaccine.
PCV20 is approved for use in individuals six weeks of age and older for the prevention of invasive pneumococcal disease caused by S. pneumoniae and for the prevention of otitis media (ear infection) caused by S. pneumoniae in infants and children aged six weeks through five years of age. PCV20 is also approved for use in adults 18 years of age and older for the prevention of pneumonia caused by Streptococcus pneumoniae.
Prevnar 20 is a 20-valent Pneumococcal Conjugate Vaccine containing S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F,14, 15B, 18C, 19A, 19F, 22F, 23F and 33F, each individually linked to non-toxic diphtheria CRM197 protein. Serotypes are each grown in a soy peptone broth and each polysaccharide is purified. Each polysaccharide is then chemically activated to make saccharide and linked to the Diphtheria CRM197 protein to form the glycoconjugate. CRM197, a nontoxic variant of diphtheria toxin, is isolated from cultures of Corynebacterium diphtheria strain C7 which has been grown in a yeast extract and casamino acids based medium or in a chemically-defined medium. CRM197 and each glycoconjugate is then purified and the individual glycoconjugates are joined to make Prevnar 20. Each 0.5ml dose of Prevnar 20 contains approximately 2.2 μg of S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F,14, 15B, 18C, 19A, 19F, 22F, 23F and 33F saccharides, 4.4 μg of 6B saccharides, 51 μg CRM197 carrier protein, 295 μg succinate buffer, 100 μg polysorbate 80, 4.4mg sodium chloride, and 125 μg aluminum as aluminum phosphate adjuvant.
